RS65007B1 - Vakcina u kombinaciji sa inhibitorom imunološke kontrolne tačke za primenu u lečenju kancera - Google Patents
Vakcina u kombinaciji sa inhibitorom imunološke kontrolne tačke za primenu u lečenju kanceraInfo
- Publication number
- RS65007B1 RS65007B1 RS20231231A RSP20231231A RS65007B1 RS 65007 B1 RS65007 B1 RS 65007B1 RS 20231231 A RS20231231 A RS 20231231A RS P20231231 A RSP20231231 A RS P20231231A RS 65007 B1 RS65007 B1 RS 65007B1
- Authority
- RS
- Serbia
- Prior art keywords
- polypeptide
- immune checkpoint
- checkpoint inhibitor
- cell
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16172760 | 2016-06-02 | ||
| PCT/EP2017/063589 WO2017207814A1 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| EP17729078.0A EP3463436B1 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65007B1 true RS65007B1 (sr) | 2024-01-31 |
Family
ID=56132759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20231231A RS65007B1 (sr) | 2016-06-02 | 2017-06-02 | Vakcina u kombinaciji sa inhibitorom imunološke kontrolne tačke za primenu u lečenju kancera |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11419927B2 (enExample) |
| EP (2) | EP3463436B1 (enExample) |
| JP (2) | JP7321709B2 (enExample) |
| AU (1) | AU2017275782B2 (enExample) |
| CA (1) | CA3026172A1 (enExample) |
| DK (1) | DK3463436T3 (enExample) |
| ES (1) | ES2965957T3 (enExample) |
| FI (1) | FI3463436T3 (enExample) |
| HR (1) | HRP20231650T1 (enExample) |
| HU (1) | HUE065176T2 (enExample) |
| LT (1) | LT3463436T (enExample) |
| PL (1) | PL3463436T3 (enExample) |
| PT (1) | PT3463436T (enExample) |
| RS (1) | RS65007B1 (enExample) |
| SI (1) | SI3463436T1 (enExample) |
| WO (1) | WO2017207814A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2751092T3 (es) | 2010-02-16 | 2020-03-30 | Ultimovacs Asa | Polipéptidos |
| LT3463436T (lt) | 2016-06-02 | 2024-01-25 | Ultimovacs Asa | Vakcina derinyje su imuninės patikros taško slopikliu, skirta vėžiui gydyti |
| GB201803178D0 (en) * | 2018-02-27 | 2018-04-11 | Univ Oslo Hf | Specific binding molecules for htert |
| US12251447B2 (en) | 2018-06-29 | 2025-03-18 | Taiho Pharmaceutical Co., Ltd. | Combined formulation comprising four linked cytotoxic T lymphocyte (CTL) epitopes and a PD-1 pathway inhibitor and methods of use thereof to treat cancer |
| KR20240046703A (ko) | 2021-06-09 | 2024-04-09 | 울티모박스 아베 | 접합체 |
| WO2024083866A1 (en) | 2022-10-17 | 2024-04-25 | Ultimovacs Asa | Cancer treatment |
| WO2024126758A2 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A nucleic acid molecule and a chimeric polypeptide |
| WO2024126737A1 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A core and a conjugate |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0013542A (pt) | 1999-08-23 | 2002-05-14 | Dana Farber Cancer Inst Inc | Moléculas b7-4 e usos para as mesmas |
| EP3225632B1 (en) | 1999-11-30 | 2020-05-06 | Mayo Foundation for Medical Education and Research | Antibodies binding to b7-h1, a novel immunoregulatory molecule |
| WO2003086459A1 (en) | 2002-04-12 | 2003-10-23 | Medarex, Inc. | Methods of treatement using ctla-4 antibodies |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| FI4209510T3 (fi) | 2008-12-09 | 2024-03-22 | Hoffmann La Roche | Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi |
| ES2751092T3 (es) * | 2010-02-16 | 2020-03-30 | Ultimovacs Asa | Polipéptidos |
| CA2793087C (en) | 2010-03-15 | 2019-07-23 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Peptides, conjugates and method for increasing immunogenicity of a vaccine |
| WO2012037551A2 (en) | 2010-09-17 | 2012-03-22 | Irx Therapeutics, Inc. | Primary cell-derived biologic and wt1 synthetic long peptide vaccine |
| EP3718556A3 (en) | 2012-08-31 | 2020-12-30 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
| GB201223386D0 (en) | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| SG10201710473VA (en) * | 2013-02-22 | 2018-02-27 | Curevac Ag | Combination of vaccination and inhibition of the pd-1 pathway |
| WO2014144885A2 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Cancer vaccines and methods of treatment using the same |
| GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| US20170035864A1 (en) | 2013-12-09 | 2017-02-09 | Bullet Biotechnology, Inc. | SPECIFIC VIRUS-LIKE PARTICLE-CpG OLIGONUCLEOTIDE VACCINES AND USES THEREOF |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| US9903102B2 (en) | 2013-12-27 | 2018-02-27 | Xiamen Solex High-Tech Industries Co., Ltd. | Concealed embedded component for a waterway system |
| SG11201606625RA (en) | 2014-02-14 | 2016-09-29 | Immune Design Corp | Immunotherapy of cancer through combination of local and systemic immune stimulation |
| US10933106B2 (en) | 2014-02-25 | 2021-03-02 | Deutsches Krebsforschungszentrum | RNA viruses for immunovirotherapy |
| NZ725459A (en) | 2014-05-13 | 2023-04-28 | Bavarian Nordic As | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
| DK3142689T3 (da) | 2014-05-13 | 2021-02-15 | Bavarian Nordic As | Kombinationsbehandling til behandling af cancer med en koppevirus, som udtrykker et tumorantigen, og et monoklonalt antistof mod tim-3 |
| US20170136127A1 (en) | 2014-07-01 | 2017-05-18 | Vicus Therapeutics, Llc | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them |
| EP3166630A4 (en) | 2014-07-07 | 2018-03-28 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| JP6820830B2 (ja) | 2014-07-18 | 2021-01-27 | ユニヴァーシティ オブ ワシントン | がんワクチン組成物およびその使用方法 |
| MX2017000836A (es) | 2014-07-18 | 2017-11-17 | Advaxis Inc | Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales. |
| US20170216403A1 (en) | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
| US20190282632A1 (en) | 2014-10-23 | 2019-09-19 | Institut Gustave Roussy | Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
| US11236139B2 (en) | 2014-11-05 | 2022-02-01 | The Regents Of The University Of California | Combination immunotherapy |
| PT3405212T (pt) | 2016-01-19 | 2020-08-25 | Pfizer | Vacinas para o cancro |
| LT3463436T (lt) | 2016-06-02 | 2024-01-25 | Ultimovacs Asa | Vakcina derinyje su imuninės patikros taško slopikliu, skirta vėžiui gydyti |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
-
2017
- 2017-06-02 LT LTEPPCT/EP2017/063589T patent/LT3463436T/lt unknown
- 2017-06-02 DK DK17729078.0T patent/DK3463436T3/da active
- 2017-06-02 JP JP2018563076A patent/JP7321709B2/ja active Active
- 2017-06-02 US US16/306,352 patent/US11419927B2/en active Active
- 2017-06-02 WO PCT/EP2017/063589 patent/WO2017207814A1/en not_active Ceased
- 2017-06-02 EP EP17729078.0A patent/EP3463436B1/en active Active
- 2017-06-02 ES ES17729078T patent/ES2965957T3/es active Active
- 2017-06-02 AU AU2017275782A patent/AU2017275782B2/en not_active Ceased
- 2017-06-02 EP EP23178501.5A patent/EP4253419A3/en active Pending
- 2017-06-02 CA CA3026172A patent/CA3026172A1/en active Pending
- 2017-06-02 FI FIEP17729078.0T patent/FI3463436T3/fi active
- 2017-06-02 RS RS20231231A patent/RS65007B1/sr unknown
- 2017-06-02 PL PL17729078.0T patent/PL3463436T3/pl unknown
- 2017-06-02 SI SI201731461T patent/SI3463436T1/sl unknown
- 2017-06-02 PT PT177290780T patent/PT3463436T/pt unknown
- 2017-06-02 HR HRP20231650TT patent/HRP20231650T1/hr unknown
- 2017-06-02 HU HUE17729078A patent/HUE065176T2/hu unknown
-
2022
- 2022-08-09 US US17/818,584 patent/US12168045B2/en active Active
- 2022-08-24 JP JP2022132995A patent/JP2022171684A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7321709B2 (ja) | 2023-08-07 |
| SI3463436T1 (sl) | 2024-02-29 |
| US20190247482A1 (en) | 2019-08-15 |
| WO2017207814A1 (en) | 2017-12-07 |
| CA3026172A1 (en) | 2017-12-07 |
| EP3463436B1 (en) | 2023-09-20 |
| EP4253419A2 (en) | 2023-10-04 |
| LT3463436T (lt) | 2024-01-25 |
| JP2022171684A (ja) | 2022-11-11 |
| DK3463436T3 (da) | 2023-12-18 |
| US20230049012A1 (en) | 2023-02-16 |
| AU2017275782B2 (en) | 2024-08-15 |
| US11419927B2 (en) | 2022-08-23 |
| ES2965957T3 (es) | 2024-04-17 |
| HRP20231650T1 (hr) | 2024-05-10 |
| EP4253419A3 (en) | 2024-05-22 |
| JP2019517508A (ja) | 2019-06-24 |
| HUE065176T2 (hu) | 2024-05-28 |
| PL3463436T3 (pl) | 2024-03-04 |
| US12168045B2 (en) | 2024-12-17 |
| PT3463436T (pt) | 2023-12-28 |
| FI3463436T3 (fi) | 2023-12-04 |
| AU2017275782A1 (en) | 2019-01-24 |
| EP3463436A1 (en) | 2019-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12168045B2 (en) | Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | |
| US20230277641A1 (en) | Telomerase polypeptide vaccine for treating cancer | |
| Ladjemi et al. | Anti-HER2 vaccines: new prospects for breast cancer therapy | |
| KR102823333B1 (ko) | 암 치료 방법 및 조성물 | |
| JP2022553192A (ja) | 癌ワクチン | |
| Agarwal et al. | Development of novel immune interventions for prostate cancer | |
| AU2016289727B2 (en) | Immunogenic preprocalcitonin peptides | |
| WO2024083866A1 (en) | Cancer treatment | |
| Venanzi et al. | Co-expression of Flt-3 ligand gene ablates tumor immunity elicited by HER-2/neu DNA vaccine in transgenic mice | |
| KR20220010712A (ko) | Wt1-양성 암을 치료하기 위한 다가 면역요법 조성물 및 사용 방법 |